- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04675632
Impact of Tibial Run Off on Clinical Outcome of Endovascular Therapy in Femoropopliteal Lesions (TALENT Study)
the Director of Vascular Surgery of Hospital of Chengdu University of Traditional Chinese Medicine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Arteriosclerosis obliterans of lower extremities (arteriosclerosis obliterans, ASO) is a common and frequently-occurring disease in middle-aged and elderly people, and also an important manifestation of atherosclerosis in lower extremities.ASO is reported to be present in approximately 12%-14% of the population, increasing to 20% of the population over the age of 75.The current treatment methods of ASO include pharmacotherapy, surgical procedures, endovascular treatment, combined surgery, and autologous peripheral blood stem cell transplantation (ASCT), etc.Endovascular treatment of ASO for lower limbs has the advantages of safety, effectiveness and fewer complications, and has become the preferred treatment for ASO.Endovascular treatment mainly includes: percutaneous transluminal angioplasty (PTA) and bare stent implantation. Currently, the most commonly used surgical options include: ordinary balloon dilatation + drug-coated balloon (DCB) dilatation + bare stent implantation.A number of studies have proved that DCB and bare stent are more effective than common PTA, but postoperative restenosis in ASO is always a difficulty.In addition to the chronic total occlusion or diffuse lesion of the lower extremity arteries, the inferior genicular artery outflow channel, age, diabetes, hemodialysis and critical limb ischemia are all related.Matsumi J, et al. found that patency of the inferior genicular artery may be an important predictor of adverse events after the SMART stent implantation in patients with popliteal artery disease, and the preservation of the distal outflow tract may be beneficial to reduce the rate of restenosis Early analysis of the patency rate of inferior genicular artery bypass found that poor outflow tract could lead to an increase in bypass thrombosis events.Matsumi J,et al. found that patency of the Early analysis of the patency rate of inferior genicular artery bypass found that poor outflow tract could lead to an increase in bypass thrombosis events. may be an important predictor of adverse events after SMART stent implantation in patients with popliteal artery disease, and the preservation of the distal outflow tract may be beneficial to reduce the rate of restenosis.Daniel M et al. conducted a retrospective analysis of 95 patients with femoral popliteal artery stent implantation and found that,for patients with poor subgenual artery outflow tract, the number of additional inferior genicular artery during femoral artery stent implantation usually leads to better clinical outcomes.the number of inferior genicular artery shown by preoperative angiography is an independent predictor of post-stent clinical outcomes.This study demonstrates the importance of distal outflow tract clinical outcomes after stent implantation.Yusuke W,et al. conducted a retrospective study on 199 patients with chronic popliteal artery occlusion and found that additional inferior genicular artery opening during stent implantation was beneficial to the patency rate of the stent and clinical results .However, the current analysis of the influence of the tibial run off on the femoral popliteal patency is mainly a retrospective study.
The purpose is to evaluate the patency of the tibial run off through a prospective multicenter observational real world study, whether it has an impact on the therapeutic effect after endovascular treatment in femoral popliteal artery , and whether one-stage reconstruction of the tibial run off can improve the postoperative patency rate of endovascular treatment.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: QIqi Wang, master
- Phone Number: 028-87766214 86-15184495605
- Email: 285510746@qq.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- Chunshuihe
-
Contact:
- Qiqi Wangqiqi, Master
- Phone Number: 86-15184495605
- Email: 285510746@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
1) Rutherford stages 2-5. 2) The femoral and popliteal artery as the target of the study has at least ≥70% stenosis or occlusion.
3) Whether it is a primary femoral and popliteal artery disease or in-stent restenosis, patients who received endovascular recanalization successfully (Residual stenosis <30% and no flow-limiting arterial dissection) can be enrolled in the group.
4) For the patients with both lower limbs to be treated, both limbs can be selected into the group.
5) Patients who failed the first treatment because the guide wire could not pass through the lesion can still be included in the group after successful endovascular interventional treatment.
6) Patients who understand the purpose of this research, volunteer to participate in the experiment, sign an informed consent form and are willing to be followed up can be included in the experiment.
7) For ipsilateral aortoiliac artery disease, patients with residual stenosis <30% can also be included in the group after intravascular reconstruction.
Exclusion Criteria:
1) Patients with acute arterial thrombosis. 2) Patients with serum creatinine level> 176μmol/L. 3) Patients with Rutherford stage 5 have foot infection grades of 2 and 3 in the preoperative WIFI (WIfI) classification.
4) Limbs that have been treated with the femoral and popliteal artery bypass surgery.
5) Patients who are known to be allergic or sensitive to contrast agents, heparin, aspirin (ASA), other anticoagulant or antiplatelet therapies, and/or paclitaxel.
6) Patients with bleeding constitution. 7) Pregnant and lactating women. 8) Patients with a history of myocardial infarction or unstable angina within 3 months.
9) Patients with a history of TIA or cerebral infarction within 3 months. 10) Patients with severe disease such as liver failure. 11) Patients with a life expectancy of less than 24 months. 12) Participating in other drug or device studies currently. 13) Patients with poor treatment compliance or deemed unsuitable for inclusion in the group by the researcher.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
The intervention group
the tibial run off would be treated through endovascular therapy
|
the most commonly used surgical options include: ordinary balloon dilatation, drug-coated balloon (DCB) dilatation and bare stent implantation.
|
the non-intervention group
the tibial run off would not be treated through endovascular therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the clinically driven target lesion revascularization(CD-TLR) rate at post-interventional
Time Frame: 24 months
|
Any reintervention within the target lesion due to symptoms or drop of ABI≥20% or >0.15 when compared to post-index procedure baseline ABI.
|
24 months
|
Changes of the patency rate of target(Femoropopliteal) lesions at post-interventional
Time Frame: baseline and 24 months
|
the patency rate of target(Femoropopliteal) lesions would be determined by vascular ultrasound,Restenosis would be diagnosed if the peak systolic velocity ratio(PSVR)≥2. 5.
|
baseline and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
vascular quality of life questionnaire(VascuQol)
Time Frame: 1 month,6 months,12 months,18 months and 24 months
|
The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL).
Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life.
|
1 month,6 months,12 months,18 months and 24 months
|
Wound,Ischemia,and foot infection(WIFI) classification system
Time Frame: 1 month,6 months,12 months,18 months and 24 months
|
The Wound, Ischemia, and foot Infection (WIfI) classification system was created to encompass demographic changes and expanding techniques of revascularization to perform meaningful analyses of outcomes in the treatment of the threatened limb,including wound,ischemia and foot infection.Each index was evaluated by very low,low,moderate and high,the very low represents no risk,the high reveals high risk of amputation.
|
1 month,6 months,12 months,18 months and 24 months
|
Changes of rutherford grade
Time Frame: 1 month,6 months,12 months,18 months and 24 months
|
Rutherford classified Peripheral arterial disease(PAD) into acute and chronic limb ischemia, emphasizing that each presentation requires different treatment algorithms.The system was based on clinical symptoms and objective findings, including Doppler, arterial brachial indices (ABI), and pulse volume recordings.Rutherford's acute limb ischemia(ALI) classification divides an extremity into viable, threatened, or irreversibly damaged categories from 0-6,the lowest reveals no hemodynamically significant occlusive disease,the highest shows functional foot no longer salvageable.
|
1 month,6 months,12 months,18 months and 24 months
|
Incidence of perioperative adverse events
Time Frame: 1 month,6 months,12 months,18 months and 24 months
|
To measure the safety of the whole procedure,adverse events including acute vascular event,major adverse events related to surgery(major amputation,death) wound be monitored.
|
1 month,6 months,12 months,18 months and 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Meng Ye, doctor, RenJi Hospital
- Principal Investigator: Ziheng Wu, doctor, Zhejiang University
- Principal Investigator: Lianrui Guo, doctor, Xuanwu Hospital, Beijing
- Principal Investigator: Xin Fang, doctor, Hangzhou First People's hospital of Medical College of Zhejiang University
- Principal Investigator: Hongfei Sang, doctor, Second Affiliated Hospital of Suzhou University
- Principal Investigator: Zibo Feng, doctor, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
- Principal Investigator: Qiang Li, doctor, Qingdao Haici hospital affiliated to Qingdao University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ChengduUTCMvs2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Femoropopliteal Artery Occlusion
-
Liyuan Hospital of Tongji Medical College, Huazhong...First People's Hospital of Hangzhou; RenJi Hospital; Chengdu University of Traditional... and other collaboratorsActive, not recruitingDrug-coated Balloon | Angioplasty | Femoropopliteal Artery OcclusionChina
-
C. R. BardCompletedPeripheral Artery Disease | Femoropopliteal Artery Occlusion | Femoropopliteal StenosisUnited States
-
Shanghai Pudong HospitalShanghai Zhongshan Hospital; RenJi Hospital; Huashan Hospital; Xuanwu Hospital,... and other collaboratorsRecruitingIn-stent Restenosis | Femoropopliteal Artery Occlusion | Atherosclerosis Obliterans | Lesion; VascularChina
-
First Affiliated Hospital of Zhejiang UniversityRecruitingFemoropopliteal Artery OcclusionChina
-
Yonsei UniversityCompleted
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Yonsei UniversityUnknownFemoropopliteal Artery DiseaseKorea, Republic of
-
SurModics, Inc.Active, not recruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Femoropopliteal Artery Occlusion | Artery Disease, PeripheralNew Zealand, United States, Belgium, Latvia, Germany, Australia, Austria, Czechia, Italy
-
Paracelsus Medical UniversityRecruitingPeripheral Arterial Occlusive Disease | Claudication, Intermittent | Femoropopliteal Artery Occlusion | Femoropopliteal Stenosis | Critical Limb-Threatening IschemiaAustria
-
Yonsei UniversityUnknownFemoropopliteal Artery DiseaseKorea, Republic of
Clinical Trials on Endovascular Therapy
-
University Hospital, Basel, SwitzerlandStryker Neurovascular; Medtronic; Swiss National Fund for Scientific Research; Phenox... and other collaboratorsRecruitingAcute Ischemic StrokeSpain, Belgium, Germany, Finland, Switzerland, United Kingdom
-
Xuanwu Hospital, BeijingFudan University; RenJi Hospital; Huashan Hospital; First Affiliated Hospital of... and other collaboratorsRecruitingChronic Limb-threatening Ischemia | Endovascular TherapyChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingRenal Artery Obstruction | Hypertension, RenovascularChina
-
Shinichi YoshimuraTerminatedIschemic StrokeJapan
-
Radiant MedicalTerminatedRenal Insufficiency | Renal Failure | Kidney FailureUnited States
-
Shanghai Zhongshan HospitalUnknownRenal Artery Obstruction | Aortic Dissection | Renal Artery Stenosis | Renal PerfusionChina
-
Radiant MedicalTerminatedAcute Myocardial InfarctionUnited States
-
Medical University of South CarolinaUniversity of California, Los Angeles; National Institute of Neurological Disorders... and other collaboratorsNot yet recruitingIschemic Stroke
-
Tianjin Huanhu HospitalRecruitingLarge Vessel Occlusion | Endovascular Procedures | Stroke, Acute IschemicChina